Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $31.6 million.

  • Cumberland Pharmaceuticals' Total Current Liabilities fell 21.80% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 21.80%. This contributed to the annual value of $31.6 million for FY2024, which is 13.01% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Total Current Liabilities stood at $31.6 million for FY2024, which was up 13.01% from $28.0 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Total Current Liabilities high stood at $31.6 million for FY2024, and its period low was $19.3 million during FY2021.
  • In the last 3 years, Cumberland Pharmaceuticals' Total Current Liabilities had a median value of $28.6 million in 2022 and averaged $29.4 million.
  • In the last 5 years, Cumberland Pharmaceuticals' Total Current Liabilities dropped by 24.89% in 2021 and then surged by 48.24% in 2022.
  • Cumberland Pharmaceuticals' Total Current Liabilities (Yearly) stood at $25.7 million in 2020, then fell by 24.89% to $19.3 million in 2021, then skyrocketed by 48.24% to $28.6 million in 2022, then fell by 2.09% to $28.0 million in 2023, then grew by 13.01% to $31.6 million in 2024.